GlaxoSmithKline Latvia SIA — Financial statements & reports

Name: Datreal.com Company Registry
Creator: Datreal.com
License: https://opendatacommons.org/licenses/by/1.0/

Income statement

Income statement
Year	Revenue	Inventory changes	Long-term investment expenses	Other operating income (by nature)	Material expenses	Labour expenses	Depreciation	Cost of goods sold	Gross profit	Selling expenses	Administrative expenses	Other operating income (by function)	Other operating expenses	Profit from equity investments	Other long-term investment income	Interest income	Investment revaluation	Interest expenses	Extraordinary income	Extraordinary expenses	Profit before taxes	Income tax provisions	Profit after taxes	Other taxes	Extraordinary dividends	Net profit
2021	10 252 080 €	-	-	-	-	-	-	9 075 117 €	1 176 963 €	884 103 €	489 251 €	900 446 €	317 481 €	0 €	0 €	184 €	-	10 735 €	-	-	376 023 €	3637 €	372 386 €	-	0 €	372 386 €
2020	19 167 078 €	-	-	-	-	-	-	17 196 211 €	1 970 867 €	1 969 575 €	1 821 360 €	3 974 217 €	1 503 130 €	0 €	0 €	118 €	-	4072 €	-	-	647 065 €	116 762 €	530 303 €	-	0 €	530 303 €

Year	Assets					Assets					Liabilities				Equity		Total liabilities & equity
Year	Cash	Securities	Receivables	Inventories	Total current assets	Investments	Intangible assets	Fixed assets	Total non-current assets	Total assets	Future housing repairs	Current liabilities	Non-current liabilities	Provisions	Capital	Total equity	Total liabilities & equity
2021	420 368 €	0 €	6 655 232 €	0 €	7 075 600 €	0 €	0 €	0 €	0 €	7 075 600 €	-	109 174 €	0 €	74 159 €	6 892 267 €	7 075 600 €	7 001 441 €
2020	2 210 475 €	0 €	5 515 678 €	985 266 €	8 711 419 €	0 €	0 €	23 111 €	23 111 €	8 734 530 €	-	1 681 216 €	0 €	533 433 €	6 519 881 €	8 734 530 €	8 201 097 €

Year	Operating cash flow	Investing cash flow	Financing cash flow	Net cash change
2021	Not available
2020	Not available